From One to One Million – Scaling Transdermal Patches from the Lab to Mass Production

Producing a successful transdermal drug formulation is a major undertaking. It can take millions of dollars and years of development. Completion of a formulation, however, only leads to your next big challenge: scaling from one lab patch to 1 million production patches. And it can be especially difficult if you lack experience in transdermal patches. Commercial production can bring a variety of complexities, ranging from perplexing quality issues and unexpected production delays to high waste. All of this can slow your time to market, increase your production costs and result in products that don’t deliver on your promise to patients.

By following a quality-by-design (QBD) approach, you can proactively address these issues and better ensure a successful product launch.

Download our e-book to learn about the four key elements of a QBD approach.